From a policy and clinical practice perspective if national malaria programs decide to support radical cure with primaquine in the absence of G6PD testing, important ethical considerations will be raised and difficult tradeoffs between ensuring patient safety and expanding access to critical treatments must be made. This evidence concerns the gene G6PD and malaria.